For the third quarter of 2026, analysts anticipate Scholar Rock will report a consensus loss of $0.85 per share on revenue of $0.30 million, with the stock currently trading at $47.33 against an average analyst target of $69.67.

Investors are primarily focused on the initial commercial launch and sales uptake of ISEMBLYD following its FDA approval in September 2026 for spinal muscular atrophy.

Management is currently scaling global operations to reach up to 50 countries while managing a cash runway that extends through late 2026. This earnings report marks the first commercial update since the company's transition from a clinical-stage biotech to a commercial-stage entity.